Predictors of switching from beta-blockers to other anti-hypertensive drugs: A review of records of 19,177 Chinese patients seen in public primary care clinics in the New Territory East, Hong Kong

Asia Pacific Family Medicine

Volumn 10, Issue 1, 2011, Pages

  Wong, Martin Cs ^a   Wang, Harry Hx ^a   Jiang, Johnny Y ^b   Leeder, Stephen ^c   Griffiths, Sian M ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

beta blocker; family practice; pharmacoepidemiology; switching

Indexed keywords

EID: 80052252576     PISSN: None     EISSN: 1447056X     Source Type: Journal    
DOI: 10.1186/1447-056X-10-10     Document Type: Review

References (37)

1. Selected major risk factors and global and regional burden of disease. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Lancet 2002 360 1347 1360 10.1016/S0140-6736(02)11403-6 12423980 (Pubitemid 35341298)
2. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS, Hypertension 2007 49 69 75 17159087 (Pubitemid 46360343)
3. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation 2006 113 85 151 10.1161/CIRCULATIONAHA.105.171600 16407573
4. Hypertension in the Asian Pacific region: the problem and the solution. Morgan T, J Hypertens 2008 26 1883 5 10.1097/HJH.0b013e32830a976e 18698225
5. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Wang TJ, Stafford RS, Arch Intern Med 1998 158 1901 1906 10.1001/archinte.158.17.1901 9759686 (Pubitemid 28440863)
6. Antihypertensive drug therapies and the risk of ischemic stroke. Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HG, de Boer A, Psaty BM, Arch Intern Med 2001 161 37 43 10.1001/archinte.161.1.37 11146696 (Pubitemid 32052141)
7. Hypertension Treatment and control in five European countries, Canada, and the United States. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M, Hypertension 2004 43 10 17 10.1161/01.HYP.0000116289.91160.73 14638619 (Pubitemid 38031904)
8. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. Hughes D, McGuire A, J Hum Hypertens 1998 12 533 7 (Pubitemid 28430222)
9. Health services research in the public healthcare system in Hong Kong: An analysis of over 1 million antihypertensive prescriptions between 2004-2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. Wong MCS, Jiang JY, Tang JL, Lam A, Fung H, Mercer SW, BMC Health Services Research 2008 8 138 10.1186/1472-6963-8-138 18578878 (Pubitemid 351962608)
10. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. Chobanian AV, Bakris GL, Black HR, et al. JAMA 2003 289 2560 72 10.1001/jama.289.19.2560 12748199 (Pubitemid 37430158)
11. Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. Wong MCS, Jiang Y, Griffiths S, Journal of Human Hypertension 2010
12. Factors associated with compliance, discontinuation and switching of calcium channel blockers in 20,156 Chinese patients. Wong MCS, Jiang JY, Griffiths SM, Am J Hypertens 2009 22 904 10
13. Profiles of Discontinuation and Switching of Thiazide Diuretics: a Cohort Study among 9,398 Chinese Hypertensive Patients. Wong MCS, Su XF, Jiang JY, Tang JL, Griffiths SM, Hypertension Research 2011
14. Beta blockers in hypertension. Panjrath GS, Messerli FH, Comprehensive Hypertension Philadelphia: Mosby Elsevier, Lip GYH, Hall HE, 2007 964
15. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. Burke TA, Sturkenboom MC, Lu S, Wenworth CE, Lin Y, Rhoads GG, J Hypertens 2006 24 1193 1200 10.1097/01.hjh.0000226211.95936.f5 16685222 (Pubitemid 43772328)
16. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Mazzaglia G, Mantovani LG, Sturkenboom MCJM, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP, J Hypertens 2005 23 2093 2100 10.1097/01.hjh.0000186832.41125.8a 16208153 (Pubitemid 41830406)
17. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire J-P, J Hum Hypertens 2005 19 607 613 10.1038/sj.jhh.1001873 15920457 (Pubitemid 41131661)
18. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. Hoer A, Gothe H, Khan ZM, Schiffhorst G, Vincze G, Haussler B, J Hum Hypertens 2007 21 744 746 10.1038/sj.jhh.1002223 17508015 (Pubitemid 47335306)
19. Adherence to antihypertensive medication and association with patient and practice factors. Inkster ME, Donnan PT, MacDonald TM, Sullivan FM, Fahey T, J Hum Hypertens 2006 20 295 297 10.1038/sj.jhh.1001981 16424861
20. Hypertension and ethnic group. Brown MJ, BMJ 2006 332 833 836 10.1136/bmj.332.7545.833 16601044
21. Gender, race, and genetic issues in cardiovascular pharmacotherapeutics. Charmey B, Meyer BR, Frishman WH, et al. Cardiovascular Pharmacotherapeutics New York: McGraw ill, Frishman WH, 1997 1347 61
22. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. Hou HH, Koshakji RP, Silberstein DJ, et al. N Engl J Med 1989 320 565 70 10.1056/NEJM198903023200905 2536896 (Pubitemid 19070541)
23. Factors associated with antihypertensive drug compliance in 83,884 Chinese patients: a cohort study. Wong MCS, Jiang Y, Griffiths S, Journal of Epidemiology and Community Health 2010 64 895 901 10.1136/jech.2009.091603 20693495
24. Realizing the benefits of eHealth in Hong Kong. Cheung NT, Health informatics, Hospital Authority, Hong Kong, http://www.ehealth.org.hk/Speaker/ Dr%20Ngai%20Tseung%20CHEUNG.pdf Accessed on 01, April, 2011
25. Population by-census. Hong Kong Special Administrative Region, China 2006 http://www.bycensus2006.gov.hk/data/data2/index.htm Accessed on 01 April, 2011
26. Beta blockers in hypertension. Panjrath GS, Messerli FH, Comprehensive Hypertension 2007, Lip GYH, Hall JE, 2007 959 970
27. Role of cardiac factors in the initial hypotensive action by beta-adrenoceptor blocking agents. Colfer HT, Cottier C, Sanchez R, Julius S, Hypertension 1984 6 145 51 6144632 (Pubitemid 14111480)
28. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Lancet 1983 2 983 86 6138591
29. Hemodynamic patterns of untreated hypertensive disease. Lund-Johansen P, Ormvik P, Hypertension: Pathophysiology, Diagnosis, and Management New York: Raven Press, Laragh JH BB, 2 1995 323 42
30. Nebivolol in the management of essential hypertension: A review. McNeely W, Goa KL, Drugs 1999 57 633 51 10.2165/00003495-199957040-00011 10235696 (Pubitemid 29196925)
31. Comparison of beta adrenergic receptor subtypes in mammalian tissues. Minneman KP, Hedberg A, Molinoff PB, J Pharmacol Exp Ther 1979 211 502 08 229209 (Pubitemid 10128320)
32. Beta blocking agents. Opie LH SE, Frishman WH et al, Drugs for the Heart Philadelphia: W.B. Saunders, Opie LH, Frishman WH, et al, 4 1995 1 30
33. Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. Messerli FH, Grossman E, Goldbourt U, JAMA 1998 279 1903 07 10.1001/jama.279.23.1903 9634263 (Pubitemid 28299288)
34. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Klingbeil AU, Schneider M, Martus P, et al. Am J Med 2003 115 41 46 10.1016/S0002-9343(03)00158-X 12867233 (Pubitemid 36831120)
35. The effects of antihypertensive therapy on left ventricular mass in elderly patients. Schulman SP, Weiss JL, Becker LC, et al. N Engl J Med 1990 322 1350 56 10.1056/NEJM199005103221904 2139175 (Pubitemid 20154478)
36. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Schiffrin EL, Park JB, Intengan HD, Touyz RM, Circulation 2000 101 1653 59 10758046 (Pubitemid 30196624)
37. Why beta blockers are not cardioprotective in elderly patients with hypertension. Grossman E, Messerli FH, Curr Cardiol Rep 2002 4 468 73 10.1007/s11886-002-0108-3 12379165